BFLY · XBRL financial data
Butterfly Network financial statements, every fiscal year
The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (BFLY's year ends in late December)
- † Share count changed about 29x in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (BFLY's year ends in late December)
- † Share count changed about 29x in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (BFLY's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | †Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (162,745) | (32,409) | (168,723) | (133,700) | (72,492) | (77,064) |
| Stock-based compensation | 11,004 | 47,798 | 42,531 | 27,480 | 21,032 | 23,435 |
| Depreciation and amortization | 1,316 | 2,090 | 5,935 | 8,700 | 8,900 | 6,700 |
| Net cash from operating activities | (81,700) | (189,187) | (169,115) | (98,820) | (41,707) | (12,700) |
| Purchases of property and equipment | 2,376 | 7,877 | 18,302 | 5,783 | 2,694 | 3,348 |
| Net cash from investing activities | (2,376) | (9,870) | (93,779) | 70,414 | (2,658) | (3,348) |
| Proceeds from issuing common stock | — | — | — | 0 | 0 | 81,006 |
| Repayments of long-term debt | — | 4,366 | — | — | — | — |
| Net cash from financing activities | 54,280 | 565,692 | 2,881 | 228 | (1,495) | 77,762 |
| Net change in cash | (29,796) | 366,635 | (260,013) | (28,178) | (45,860) | 61,714 |
- † Share count changed about 29x in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 3844 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 3844 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Butterfly Network | 122,301 | 32,598 | (2,266)* | not reported | 10.3 quarters | 10-QSep 30, 2026 |
| Pulse Biosciences | 101,620 | 434 | (18,709)* | 71.3M | 5.4 quarters | 10-QJun 30, 2026 |
| Orthopediatrics | 17,141 | 72,661 | 4,506* | 26.1M | — | 10-QSep 30, 2026 |
| Ceribell | 41,989 | 29,341 | (13,078)* | 38.8M | 7.8 quarters | 10-QSep 30, 2026 |
| EBR Systems | 59,350 | 2,637 | (17,194)* | 75.3M | 5.0 quarters | 10-QJun 30, 2026 |
| Delcath Systems | 47,521 | 29,133 | 5,712* | 34.7M | — | 10-QJun 30, 2026 |
| Axogen | 328,888 | 75,834 | 16,536* | 59.7M | — | 10-QSep 30, 2026 |
| Angiodynamics | 33,973 | 80,915 | (15,330) | 42.1M | 2.2 quarters | 10-QAug 31, 2026 |
| Outset Medical | 35,005 | 31,635 | (9,635)* | 18.8M | 15.3 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.